COMP <GO>
IRON vs ACAD // RETURN ON INVESTED CAPITAL (ROIC)
Disc Medicine Inc. (NASDAQ) VS. ACADIA Pharmaceuticals Inc. (NASDAQ) • 15-METRIC TALLY: IRON 4
— ACAD 6
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: ACAD
LAST: $78.62 (-2.75%) • MKT CAP: $3.59B
roic
-27.50%
LAST: $20.47 (-0.58%) • MKT CAP: $3.55B
roic
7.90%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (IRON VS. ACAD)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | IRON | ACAD | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 91.70% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | -27.50% | 7.90% | -35.40 | ACAD | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 31.2x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -4.93% | 2.94% | -7.87 | ACAD | /fcf-yield <GO> |
| Operating Margin | -22.90% | 9.80% | -32.70 | ACAD | /operating-margins <GO> |
| Net Profit Margin | -20.60% | 36.50% | -57.10 | ACAD | /net-margins <GO> |
| Revenue Growth (YoY) | 16.50% | 11.90% | +4.60 | IRON | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 26.00 | 6.26 | +19.74 | IRON | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 7/9 | -2.00 | ACAD | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 62.4 | 45.7 | +16.70 | IRON | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.90 | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 20.0x | 8.5x | +11.50 | ACAD | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $3.59B | $3.55B | $40.9M | IRON | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | IRON REV | ACAD REV | IRON GROSS % | ACAD GROSS % | IRON FCF | ACAD FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $660.9M | $1.07B | — | 91.7% | -$181.3M | $105.1M |
| FY 2024 | $363.2M | $957.8M | — | 91.5% | -$94.4M | $157.2M |
| FY 2023 | $255.2M | $726.4M | — | — | -$73.5M | $16.7M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
IRON // BETA 0.90
ACAD // BETA —